Clinical Trial Update: Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of decitabine, arsenic trioxide, and ascorbic acid for myelodysplastic syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Ascorbic acid (Vitamin C)
• Dacogen (decitabine)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: Duke University | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2013-01-28